Major News on a falling Market $TSLA $TWTR $TRIP $PEP $AIG $CBS $WYNN $GRPN

U.S. stock futures are down sharply in premarket trading Thursday amid a wider global market selloff as falling crude prices once again take their toll on markets.

Brent crude was down $0.57 to $30.27 per barrel while West Texas crude contracts for March delivery were down $0.98 to $26.47 per barrel.

Asian markets once again led the way down as Hong Kong's Hang Seng closed trading 3.9% lower and Japan's Nikkei fell 2.3%. The Shanghai Composite Index is closed this week in recognition of China's Lunar New Year holiday.

In Europe, France's CAC 40 was falling the hardest, down nearly 4%, while the German DAX and U.K. FTSE 100 were down 2.2% and 2.01%, respectively.

Today, Federal Reserve Chair Janet Yellen continues her testimony before Congress. Yellen began her testimony Wednesday, telling U.S. lawmakers that the central bank recognizes that there are still plenty of obstacles for the U.S. economy to overcome. She did not, however, give any solid indications on what policy tweaks the bank was prepared to make to overcome those headwinds.

The last leg of earnings season continues today. More than 75% of company's scheduled to report their quarterly results have done so already.

Why $CRTO is UP 18% #PreMarketMover ?

Criteo crossed $1 billion in revenue in 2015. Criteo (NASDAQ: CRTO) reported Q4 EPS of EUR0.66, EUR0.26 better than the analyst estimate of EUR0.40. Revenue for the quarter came in at EUR146 million versus the consensus estimate of EUR138.2 million.



SEE ALSO: Wednesday's Scanner

$AKAM today's scanner #PreMarketMover

Cloud computing company Akamai saw stocks pop after it reported earnings and revenue that beat analysts' expectations. The enterprise software company posted earnings of 72 cents per share on revenue of $579 million, excluding items, better than the 62 cents on $569 million expected by Wall Street.

Akamai Technologies (NASDAQ: AKAM) reported Q4 EPS of $0.72, $0.10 better than the analyst estimate of $0.62. Revenue for the quarter came in at $579 million versus the consensus estimate of $560.72 million.

The Company also announces today that its Board of Directors has authorized a new $1 billion share repurchase program, effective from February 9, 2016 through December 31, 2018. The Company's goal for this program is to offset the dilution created by its employee equity compensation programs and provide the flexibility to increase its capital distributions to shareholders as business and market conditions warrant.



SEE ALSO: Wednesday's Scanner

$AUPH today's scanner Announces Preliminary Topline Data #BeforeBell @ $2.73 UP 25%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) announced today that it has completed a preliminary analysis of its AURION (Aurinia early Urinary protein Reduction Predicts Response) study. In the first seven patients that have reached at least eight weeks of therapy in the AURION study, 100% (7/7) have achieved at least a 25% reduction in proteinuria compared to study entry. A 25% reduction in proteinuria has been shown to be predictive of a positive clinical response at 24weeks. All of the other pre-specified eight week biomarkers of active lupus nephritis (LN) have also improved and are trending towards normalization. These biomarkers have also been shown to be predictive of a positive clinical response at 24 weeks.



SEE ALSO: Monday's Scanner

$SGMO today's scanner on FDA Clearance #PreMarketGainers @ $6.40 UP 13% TP @ $7

RICHMOND, Calif., Feb. 8, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I). The SB-318 IND application is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-318-1502) designed to assess the safety, tolerability and potential efficacy of SB-318 in adults with varying severities of MPS I.



SEE ALSO: Monday's Scanner

$APOL today's scanner on #NEWS taken private in $1.1 billion deal #PreMarketGainers @ $8.82 UP 27% TP @ $9.50's

Apollo Education Group Inc. said Monday it had reached a deal to be taken private by a group of investors including Apollo Global Management LLC in a $1.1 billion deal, as the struggling education company attempts to overhaul its University of Phoenix operations.



SEE ALSO: Monday's Scanner

$TTMI #NEWS: Strong On High Volume today's scanner #Realtime @ $5.94 UP 20%

• TTMI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.0 million.
• TTMI has traded 95,547 shares today.
• TTMI is trading at 4.75 times the normal volume for the stock at this time of day.
• TTMI is trading at a new high 5.24% above yesterday's close.

$BSI today's scanner on Acquisition Offer #NEWS #PreMarketGainers @ $4.35 UP 19%

Alon Blue Square Announces Receipt of Offer for Acquisition of Control of the Company

Alon Blue Square Israel Ltd. (BSI) (the "Company") announced today that it received an offer pursuant to which a company in the Zeevi Group would acquire 51% of the Company's outstanding shares from Alon Retail Ltd., a major Company shareholder, for NIS 85 million. In addition, the purchaser would obtain a three year option to acquire an additional 21% of the Company's shares from Alon Retail at the same price per share.

$MFLX today's scanner Buyout #NEWS #PreMarketGainers @ $23.00 UP 40%

Chinese manufacturing conglomerate Suzhou Dongshan Precision Manufacturing Co. agreed to buy Multi-Fineline Electronix Inc. for $610 million.

$GLUU #NEWS: on Profits From Kardashian Game

Partnership With Taylor Swift today's scanner #PreMarketGainers @ $2.44 UP 22% technically Resistance @ $2.45 with price target @ $2.60 Goal 7%

Glu Mobile Inc. (NASDAQ:GLUU) shares were up almost 28% during after-hours trading yesterday. The stock surge came after the mobile game company reported upbeat fourth-quarter fiscal year 2015 (4QFY15) earnings results and a multi-year partnership with Taylor Swift.

$VHC today's scanner #NEWS: wins suit on patent dispute

$AAPL ordered to pay Virtex more than $625 ml, $VHC  #PreMarketGainers @ $9.35 UP 95%

Apple (AAPL) must pay more than $625 million in a patent dispute, as deemed by a federal jury in Texas on Wednesday, Reuters reported in the late afternoon. 
The consumer electronics giant was found to have used patent holder VirnetX Holding‘s (VHC) Internet security technology without its OK, in Apple’s FaceTime and iMessage features, the report said. 
Some of the intellectual property has to do with VPNs, or virtual private networking. VirnetX stock shot up more than 89% after hours, after vaulting 29.8% in Wednesday’s regular session, to 4.79. 

Apple stock slipped 0.5% after hours, following a 2% rise during a trading day in which it regained the title of biggest stock in market cap from Google-owner Alphabet (GOOGL).

#NEWS: $VLTC today's scanner Here's Why These Small Caps Could Be Ready To Rally

$HNSN today's scanner FDA Clearance #Realtime @ $5.00 UP 56%

MOUNTAIN VIEW, CA--(Marketwired - Feb 2, 2016) - Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the Magellan™ Robotic Catheter eKit (MRC eKit). The MRC eKit is the company's latest addition to the family of approved Magellan Robotic Catheters and helps extend robotic capabilities and control throughout procedures in the peripheral vasculature. With the MRC eKit, physicians will now have robotic control of 3rd party microcatheters through the existing Magellan Robotic Catheter 6Fr architecture. This added ability has the potential to help reduce procedure times and radiation exposure.

Why $AKER is UP 172% #PreMarketGainers @ $3.18 ?

STAVANGER, Norway -- Aker Solutions' maintenance, modifications and operations (MMO) business in Norway has secured two contracts for work at North Sea fields operated by ConocoPhillips.

The company received a framework agreement for a fixed period of five years to become ConocoPhillips' main supplier of maintenance and modifications work offshore Norway. The agreement may be extended by up to three years and covers work on all installations at the Ekofisk and Eldfisk fields offshore Norway, starting in February.

#NEWS: $NEOS $MPO 5 Stocks Under $10 Set to Soar

NEOS - Neos Therapeutics

Another under-$10 stock that's starting to trend within range of triggering a big breakout trade is Neos Therapeutics (NEOS) , which develops, manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. This stock has been smacked lower by the sellers over the last six months, with shares dropping sharply lower by 52.7%.

Why $AXLL is UP 71% #PreMarketGainers @ $16.75 ?

Westlake Chemical Corporation (NYSE: WLK) announced tday that it has submitted a proposal to acquire all of the outstanding shares of Axiall Corporation (NYSE: AXLL) for $20.00 per share (comprised of $11.00 in cash and 0.1967 of a Westlake share, which represented a value of $9.00 based on Westlake's closing price on January 22, 2016, the last trading day before Westlake made its proposal).

Why $GIMO is UP 16% #AfterHoursGainers @ $25.75 ?

Gigamon Inc (NASDAQ:GIMO) announced its quarterly earnings results on Thursday. The company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.06, Market Beat reports. The company earned $67 million during the quarter, compared to analysts’ expectations of $62.76 million. During the same period last year, the firm earned $0.18 earnings per share. Gigamon’s revenue for the quarter was up 30.8% on a year-over-year basis.

Why $AMDA is UP 30% #Realtime @ $2.50 ?

SALT LAKE CITY, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Amedica Corporation (AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce all four submissions to the Orthopaedic Research Society (“ORS”) Annual Meeting were accepted for presentation occurring March 5-8, 2016 in Orlando, Florida.  

$UA Revenue Rises 31% #BeforeBell @ $77.25 UP 13%

Under Armour UA +1.47% profit and revenue surged in the fourth quarter, propelled by growing footwear sales, and prompting the company to offer a better-than-expected outlook.

Investors cheered the strong results and sent shares up 14% in pre-market trading.

Why $NEOS is UP 60% #PreMarketGainers @ $15.00 ?

DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that the U.S. Food and Drug Administration (FDA) approved Adzenys XR-ODT™ for the treatment of ADHD in patients six years and older. With this approval, Adzenys XR-ODT is the first and only extended-release orally disintegrating tablet (ODT) for the treatment of ADHD.